Literature DB >> 18691484

Incidence of Pseudomonas aeruginosa bacteremia: a population-based study.

Majdi N Al-Hasan1, John W Wilson, Brian D Lahr, Jeanette E Eckel-Passow, Larry M Baddour.   

Abstract

BACKGROUND: The incidence of Pseudomonas aeruginosa bacteremia has not been defined in a population-based investigation.
METHODS: We performed a retrospective, population-based incidence study using resources of the Rochester Epidemiology Project of Olmsted County, Minnesota. We identified all Olmsted County residents with P. aeruginosa bacteremia between January 1, 1997, and December 31, 2006, by microbiology records in the only 2 laboratories in the county. Medical records were reviewed to confirm diagnosis, residency status, and clinical characteristics.
RESULTS: Age-adjusted incidence per 100,000 person-years was 10.8 (95% confidence interval [CI], 7.5-14.0) in men and 3.7 (95% CI, 2.2-5.2) in women for total P. aeruginosa bacteremia, and 8.4 (95% CI, 5.5-11.2) in men and 2.5 (95% CI, 1.3-3.8) in women for monomicrobial P. aeruginosa bacteremia. There was no significant change in incidence of total P. aeruginosa bacteremia during the past decade (P=.418). Incidence increased exponentially with age, with a greater magnitude of increase in men compared with women for total and monomicrobial P. aeruginosa bacteremia (P=.007 and P=.015, respectively). In patients with monomicrobial P. aeruginosa bacteremia, the median age was 69 years, and 78.4% of cases were either nosocomial or health care associated. Most patients had multiple comorbid conditions. The urinary tract was the most common primary source of infection. The 28-day all-cause mortality of monomicrobial P. aeruginosa bacteremia was 25.5%. In vitro susceptibility to ciprofloxacin was 95.3%.
CONCLUSION: To our knowledge, this is the first population-based incidence study of P. aeruginosa bacteremia. The incidence of P. aeruginosa bacteremia has remained stable during the past decade. Fluoroquinolone susceptibility is high among local P. aeruginosa bacteremia isolates.

Entities:  

Mesh:

Year:  2008        PMID: 18691484      PMCID: PMC2615391          DOI: 10.1016/j.amjmed.2008.03.029

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  24 in total

1.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Authors:  Cheol-In Kang; Sung-Han Kim; Hong-Bin Kim; Sang-Won Park; Young-Ju Choe; Myoung-Don Oh; Eui-Chong Kim; Kang-Won Choe
Journal:  Clin Infect Dis       Date:  2003-08-23       Impact factor: 9.079

2.  Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  A C Gales; R N Jones; J Turnidge; R Rennie; R Ramphal
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

3.  Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa.

Authors:  L Aliaga; J D Mediavilla; J Llosá; C Miranda; M Rosa-Fraile
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-11       Impact factor: 3.267

4.  Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998.

Authors:  A C Fluit; M E Jones; F J Schmitz; J Acar; R Gupta; J Verhoef
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

5.  Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota.

Authors:  Daniel Z Uslan; Sarah J Crane; James M Steckelberg; Franklin R Cockerill; Jennifer L St Sauver; Walter R Wilson; Larry M Baddour
Journal:  Arch Intern Med       Date:  2007-04-23

6.  Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa.

Authors:  Stephen Osmon; Suzanne Ward; Victoria J Fraser; Marin H Kollef
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

7.  Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa.

Authors:  S Blot; K Vandewoude; E Hoste; F Colardyn
Journal:  J Hosp Infect       Date:  2003-01       Impact factor: 3.926

8.  Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey.

Authors:  J-W Decousser; P Pina; F Picot; C Delalande; B Pangon; P Courvalin; P Allouch
Journal:  J Antimicrob Chemother       Date:  2003-04-14       Impact factor: 5.790

9.  Bacteraemia in Europe--antimicrobial susceptibility data from the MYSTIC surveillance programme.

Authors:  Serhat Unal; Robert Masterton; Herman Goossens
Journal:  Int J Antimicrob Agents       Date:  2004-02       Impact factor: 5.283

10.  International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

View more
  28 in total

1.  Influence of referral bias on the clinical characteristics of patients with Gram-negative bloodstream infection.

Authors:  M N Al-Hasan; J E Eckel-Passow; L M Baddour
Journal:  Epidemiol Infect       Date:  2011-02-01       Impact factor: 2.451

2.  Outcomes in Documented Pseudomonas aeruginosa Bacteremia Treated with Intermittent IV Infusion of Ceftazidime, Meropenem, or Piperacillin-Tazobactam: A Retrospective Study.

Authors:  Francine Kwee; Sandra A N Walker; Marion Elligsen; Lesley Palmay; Andrew Simor; Nick Daneman
Journal:  Can J Hosp Pharm       Date:  2015 Sep-Oct

3.  Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gram-negative BSI.

Authors:  M N Al-Hasan; J E Eckel-Passow; L M Baddour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-08       Impact factor: 3.267

4.  Epidemiology and outcome of Gram-negative bloodstream infection in children: a population-based study.

Authors:  M N Al-Hasan; W C Huskins; B D Lahr; J E Eckel-Passow; L M Baddour
Journal:  Epidemiol Infect       Date:  2010-07-02       Impact factor: 2.451

5.  Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.

Authors:  Chi Hyun Kim; Hee Young Kang; Bo Ra Kim; Hyejin Jeon; Yoo Chul Lee; Sang Hwa Lee; Je Chul Lee
Journal:  J Microbiol       Date:  2016-01-05       Impact factor: 3.422

6.  Epidemiology and outcome of Klebsiella species bloodstream infection: a population-based study.

Authors:  Majdi N Al-Hasan; Brian D Lahr; Jeanette E Eckel-Passow; Larry M Baddour
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

7.  Bacteremia complicating gram-negative urinary tract infections: a population-based study.

Authors:  Majdi N Al-Hasan; Jeanette E Eckel-Passow; Larry M Baddour
Journal:  J Infect       Date:  2010-01-28       Impact factor: 6.072

Review 8.  Population-based epidemiology and microbiology of community-onset bloodstream infections.

Authors:  Kevin B Laupland; Deirdre L Church
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

9.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

10.  Seasonal variation in Escherichia coli bloodstream infection: a population-based study.

Authors:  M N Al-Hasan; B D Lahr; J E Eckel-Passow; L M Baddour
Journal:  Clin Microbiol Infect       Date:  2009-10       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.